ILUVIEN (fluocinolone acetonide) by Eurofarma Laboratórios is corticosteroid hormone receptor agonists [moa]. First approved in 2014.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
ILUVIEN is a long-acting corticosteroid implant (fluocinolone acetonide) administered intravitreally to treat chronic inflammation in the eye. It works via corticosteroid hormone receptor agonism to suppress inflammatory pathways. The product is a sustained-release formulation designed for patients requiring prolonged ocular anti-inflammatory therapy.
With LOE approaching in 2.4 years and moderate competitive pressure (15), brand teams should expect declining market share and eventual transition planning toward generic phase.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant
Worked on ILUVIEN at Eurofarma Laboratórios? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
Working on ILUVIEN offers exposure to specialty ophthalmology commercial execution, intraocular device-drug hybrid products, and reimbursement complexity; however, the short runway to LOE (2.4 years) limits long-term career growth on this specific asset. Professionals joining this team should expect focus on defending market position, managing competitive entry, and planning post-LOE transitions.